AI Summary
We reviewed 617 live results for skyrizi risankizumab sdn bhd and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biologics and Immunology.
Compare skyrizi risankizumab sdn bhd with TopFind
Comparison Table
Recommended
Skyrizi (risankizumab) Sdn Bhd
Source: AbbVie Malaysia
Description
The Malaysian-market specific supply of Skyrizi, indicated for moderate-to-severe plaque psoriasis and related conditions. It is provided through hospital-based clinical channels and specialized pharmacies.
Best for
Malaysian medical services, Psoriasis treatment and Rheumatology care
Rating
Skyrizi (risankizumab)
Source: AbbVie Pharmaceuticals (Thailand) Ltd.
Description
Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading.
Best for
Plaque psoriasis patients, Psoriatic arthritis management, Crohn's disease treatment and Long Term biologic therapy
Rating
Skyrizi (risankizumab) 150mg
Source: AbbVie Singapore
Description
Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia.
Best for
Regional medical reference, Singapore Based patients and Biologic therapy information
Rating
| Compare | Skyrizi (risankizumab) Sdn Bhd | Skyrizi (risankizumab) | Skyrizi (risankizumab) 150mg |
|---|---|---|---|
| Source | AbbVie Malaysia | AbbVie Pharmaceuticals (Thailand) Ltd. | AbbVie Singapore |
| Description | The Malaysian-market specific supply of Skyrizi, indicated for moderate-to-severe plaque psoriasis and related conditions. It is provided through hospital-based clinical channels and specialized pharmacies. | Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading. | Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia. |
| Best for | Malaysian medical services, Psoriasis treatment and Rheumatology care | Plaque psoriasis patients, Psoriatic arthritis management, Crohn's disease treatment and Long Term biologic therapy | Regional medical reference, Singapore Based patients and Biologic therapy information |
| Action | |||
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Skyrizi (risankizumab) Sdn Bhd from AbbVie Malaysia."
I picked this because Ensures access to the authentic IL-23 inhibitor within Malaysia's pharmaceutical regulatory framework.